Literature DB >> 25167596

Schedules of controlled substances: placement of suvorexant into Schedule IV. Final rule.

.   

Abstract

With the issuance of this final rule, the Deputy Administrator of the Drug Enforcement Administration (DEA) places the substance [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (suvorexant), including its salts, isomers, and salts of isomers, into schedule IV of the Controlled Substances Act. This scheduling action is pursuant to the Controlled Substances Act which requires that such actions be made on the record after opportunity for a hearing through formal rulemaking. This action imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule IV controlled substances on persons who handle (manufacture, distribute, dispense, import, export, engage in research, conduct instructional activities, or possess), or propose to handle suvorexant.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25167596

Source DB:  PubMed          Journal:  Fed Regist        ISSN: 0097-6326


  6 in total

Review 1.  Suvorexant in insomnia: efficacy, safety and place in therapy.

Authors:  Danielle N Rhyne; Sarah L Anderson
Journal:  Ther Adv Drug Saf       Date:  2015-10

2.  Implications of Recent Drug Approvals for Older Adults.

Authors:  Christine Eisenhower; Michael Koronkowski; Zachary Marcum
Journal:  Ann Longterm Care       Date:  2016-01-14

Review 3.  Suvorexant: first global approval.

Authors:  Lily P H Yang
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

4.  Suvorexant: The first orexin receptor antagonist to treat insomnia.

Authors:  Ashok K Dubey; Shailendra S Handu; Pramod K Mediratta
Journal:  J Pharmacol Pharmacother       Date:  2015 Apr-Jun

5.  Is suvorexant a better choice than alternative hypnotics?

Authors:  Daniel F Kripke
Journal:  F1000Res       Date:  2015-08-03

Review 6.  Suvorexant: a promising, novel treatment for insomnia.

Authors:  Joyce K Lee-Iannotti; James M Parish
Journal:  Neuropsychiatr Dis Treat       Date:  2016-02-25       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.